{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:55:03Z","timestamp":1773762903154,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s11886-016-0784-z","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T05:37:40Z","timestamp":1476682660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Angiotensin-Neprilysin Inhibition as a Paradigm for All?"],"prefix":"10.1007","volume":"18","author":[{"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"issue":"4","key":"784_CR1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","volume":"61","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61(4):391\u2013403.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"784_CR2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","volume":"63","author":"AP Ambrosy","year":"2014","unstructured":"Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"784_CR3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1161\/CIRCHEARTFAILURE.115.002064","volume":"8","author":"EF Lewis","year":"2015","unstructured":"Lewis EF. Activities worth living for: call to action beyond prognosis. Circ Heart Fail. 2015;8(2):231\u20132.","journal-title":"Circ Heart Fail"},{"issue":"3","key":"784_CR4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606\u201319.","journal-title":"Circ Heart Fail"},{"issue":"12","key":"784_CR5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jacc.2012.12.038","volume":"61","author":"S Blecker","year":"2013","unstructured":"Blecker S, Paul M, Taksler G, et al. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61(12):1259\u201367.","journal-title":"J Am Coll Cardiol"},{"key":"784_CR6","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and The Heart Failure Society of America. Circulation. 2016; in press. This represents the updated US treatment guidelines for use of sacubitril\/valsartan in stage C chronic HFrEF."},{"key":"784_CR7","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;in press. This represents the updated European treatment guidelines for use of sacubitril\/valsartan in stage C chronic HFrEF."},{"key":"784_CR8","doi-asserted-by":"crossref","unstructured":"The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293\u2013302.","DOI":"10.1056\/NEJM199108013250501"},{"issue":"10","key":"784_CR9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2015.01.033","volume":"65","author":"E Braunwald","year":"2015","unstructured":"Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65(10):1029\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"9230","key":"784_CR10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","volume":"356","author":"JL Rouleau","year":"2000","unstructured":"Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356(9230):615\u201320.","journal-title":"Lancet"},{"issue":"8","key":"784_CR11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106(8):920\u20136.","journal-title":"Circulation"},{"issue":"2","key":"784_CR12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103\u201311.","journal-title":"Am J Hypertens"},{"issue":"11","key":"784_CR13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. This represents the primary result publication of phase III PARADIGM-HF trial evaluating the efficacy and safety of LCZ696 compared with enalapril in patients with chronic HFrEF.","journal-title":"N Engl J Med"},{"issue":"9744","key":"784_CR14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875\u201385.","journal-title":"Lancet"},{"issue":"30","key":"784_CR15","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","volume":"36","author":"AS Desai","year":"2015","unstructured":"Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990\u20137.","journal-title":"Eur Heart J"},{"issue":"38","key":"784_CR16","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, Fu M, Bayram E, Chen CH, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576\u201384.","journal-title":"Eur Heart J"},{"issue":"3","key":"784_CR17","doi-asserted-by":"crossref","first-page":"e002744","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","volume":"9","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril\/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail. 2016;9(3):e002744.","journal-title":"Circ Heart Fail"},{"key":"784_CR18","doi-asserted-by":"crossref","unstructured":"Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016;9(1).","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560"},{"issue":"1","key":"784_CR19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54\u201361.","journal-title":"Circulation"},{"issue":"23","key":"784_CR20","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","volume":"373","author":"B Claggett","year":"2015","unstructured":"Claggett B, Packer M, McMurray JJ, et al. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015;373(23):2289\u201390.","journal-title":"N Engl J Med"},{"issue":"9851","key":"784_CR21","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387\u201395.","journal-title":"Lancet"},{"key":"784_CR22","doi-asserted-by":"crossref","unstructured":"O\u2019Connor CM, Fiuzat M, Lindenfeld J. Are we really in love with old therapies? JACC Heart Fail. 2016.","DOI":"10.1016\/j.jchf.2016.02.011"},{"issue":"11","key":"784_CR23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133(11):1115\u201324.","journal-title":"Circulation"},{"issue":"5","key":"784_CR24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","volume":"4","author":"JB King","year":"2016","unstructured":"King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4(5):392\u2013402.","journal-title":"JACC Heart Fail"},{"key":"784_CR25","doi-asserted-by":"crossref","unstructured":"Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJV, Solomon SD. Cost Effectiveness Analysis of Sacubitril\/Valsartan vs. Enalapril in Patients with Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. 20016; 1(6): 666\u2013672.","DOI":"10.1001\/jamacardio.2016.1747"},{"issue":"19","key":"784_CR26","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","volume":"66","author":"J Simpson","year":"2015","unstructured":"Simpson J, Jhund PS, Silva Cardoso J, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015;66(19):2059\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"784_CR27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1161\/CIRCHEARTFAILURE.115.002271","volume":"8","author":"M Vaduganathan","year":"2015","unstructured":"Vaduganathan M, Butler J, Pitt B, et al. Contemporary drug development in heart failure: call for hemodynamically neutral therapies. Circ Heart Fail. 2015;8(4):826\u201331.","journal-title":"Circ Heart Fail"},{"issue":"8","key":"784_CR28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199902253400804","volume":"340","author":"DL Dries","year":"1999","unstructured":"Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340(8):609\u201316.","journal-title":"N Engl J Med"},{"issue":"18","key":"784_CR29","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","volume":"344","author":"DV Exner","year":"2001","unstructured":"Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344(18):1351\u20137.","journal-title":"N Engl J Med"},{"key":"784_CR30","doi-asserted-by":"crossref","unstructured":"Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18: 1193-202. .","DOI":"10.1002\/ejhf.548"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-016-0784-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-016-0784-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-016-0784-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T17:25:43Z","timestamp":1568481943000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-016-0784-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1007\/s11886-016-0784-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]},"article-number":"115"}}